Halozyme Therapeutics' record-breaking 2024 revenue exceeded $1B, with strong 2025 growth projections led by DARZALEX & VYVGART.

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

A LOCAL personal trainer wants to spread awareness of a rare disease he was diagnosed with that can severely affect motor ...

SE (NASDAQ:ARGX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst ...

"The suicides are a result of not knowing there is support, not being able to reach out for help to access the support that ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...